Transferrins TRIZ Cases

Transferrin receptor-mediated uptake helps an scFv cross the blood-brain barrier and release inside target cells through pH- or enzyme-sensitive linkers.

A ferritin nanocage stabilizes TRAIL trimers and adds cancer-targeting peptides to extend bloodstream half-life and reduce off-target effects.

Transferrin-mediated uptake and cleavable linkers help trastuzumab scFv cross brain, eye, and tumor barriers for targeted intracellular delivery.

Transferrin receptor uptake and a cleavable linker help an scFv antibody cross brain and eye barriers and release inside target cells.

Transferrin receptor uptake and cleavable linkers help an scFv fusion cross brain, eye, and tumor barriers for targeted intracellular release.

An scFv fused to transferrin uses a cleavable linker to cross brain and eye barriers, improve intracellular exposure, and limit off-target effects.

Transferrin receptor-mediated uptake and a cleavable linker help romosozumab scFv cross brain and eye barriers with lower off-target effects.

Transferrin receptor uptake and cleavable linkers help secukinumab scFv cross brain, eye, and tumor barriers for targeted intracellular release.

Transferrin receptor-mediated uptake and cleavable linkers help ravulizumab scFv cross biological barriers and release inside target cells.

An scFv-transferrin fusion uses transcytosis and cleavable linkers to cross brain and eye barriers and release romiplostim inside target cells.

Transferrin receptor-mediated scFv fusion improves intracellular uptake across brain, eye, and tumor barriers while limiting off-target exposure.

Transferrin receptor-mediated uptake helps a lecanemab scFv cross brain and eye barriers, with cleavable release to limit off-target exposure.

Transferrin-linked ofatumumab scFv crosses brain, eye, and tumor barriers while avoiding Fc-driven immune activity and enabling intracellular release.

Transferrin receptor-mediated uptake and cleavable linkers help scFv antibodies cross brain, eye, and tumor barriers for targeted intracellular release.

An scFv fused to transferrin uses receptor-mediated transcytosis and cleavable linkers to cross barriers and release cargo inside target cells.

Transferrin receptor-mediated uptake helps an ixekizumab scFv cross brain, eye, and tumor barriers with cleavable intracellular release.

An exidavnemab scFv fused to transferrin uses receptor-mediated uptake and cleavable linkers to cross barriers and release inside target cells.

A transferrin-linked gosuranemab scFv uses receptor-mediated uptake and cleavable linkers to cross barriers and release inside target cells.

A cleavable scFv-transferrin fusion uses transferrin receptor endocytosis to cross brain and eye barriers and release antibody cargo inside cells.

A transferrin-linked scFv uses receptor-mediated uptake and environment-sensitive cleavage to cross brain and eye barriers with targeted intracellular release.

Microbial cholesterol-catabolizing genes are targeted to liver and arterial cells to break down accumulated lipids that native metabolism cannot clear.

Transferrin receptor uptake and a cleavable linker help belimumab scFv cross brain and eye barriers for controlled intracellular release.

Transferrin-linked basiliximab scFv uses receptor-mediated uptake and cleavable linkers to cross barriers and improve intracellular exposure.

Transferrin receptor-mediated uptake and cleavable release help brolucizumab scFv cross brain and eye barriers and reach target cells.

An Fc-free scFv fused to transferrin uses barrier transcytosis and environment-sensitive cleavage to boost brain, eye, and tumor cell exposure.

Redox-triggered platelet lysate proteins form bioactive microparticles with tunable surface topography, improving biocompatibility and production efficiency.

Transferrin receptor-mediated uptake helps an scFv cross brain and eye barriers, then release inside target cells via cleavable linkers.

Transferrin-linked cetuximab scFv crosses brain, eye, and tumor barriers, then cleaves intracellularly to improve exposure and specificity.

Transferrin receptor transport helps cinpanemab scFv cross brain and eye barriers, while cleavable linkers limit exocytosis and release it in target cells.

Transferrin receptor-mediated uptake helps a cleavable crenezumab scFv fusion cross brain and eye barriers while limiting off-target exposure.

Transferrin-linked canakinumab scFv uses receptor-mediated uptake and cleavable linkers to cross barriers and release inside target cells.

Transferrin receptor-mediated uptake helps alemtuzumab scFv cross brain, eye, and tumor barriers with cleavable intracellular release.